Archives: Speakers

Shrey Grover is the strategy leader at Marsh Cyber UK, where he shapes the development of business-led products and propositions designed to deliver distinctive value to clients navigating an increasingly complex cyber risk landscape. A core part of his role is leading and supporting teams across the business, bringing together diverse expertise to translate strategy into execution. His work sits at the intersection of commercial strategy, client advisory, and innovation — translating market dynamics into propositions that resonate with the most sophisticated buyers of cyber insurance. Shrey is particularly interested in the role of artificial intelligence as a catalyst for enterprise productivity: how organisations can move beyond experimentation to embed AI thoughtfully and durably into how they operate and serve clients. He brings a perspective shaped by close engagement with senior stakeholders globally and a conviction that competitive advantage comes from disciplined strategy paired with genuine curiosity about what comes next.

With 18 years of experience in multinational pharmaceutical companies and CROs, including Roche, GlaxoSmithKline, Sanofi, and Kandiya, she specializes in regulatory affairs and registration strategy for innovative drugs and biologics in China. As Head of the Registration Affairs and Strategy Department, Susan Kong leads end-to-end product registration planning from IND to NDA, overseeing lifecycle regulatory pathways. Her expertise spans oncology, immunology, anti-infectives, CNS, and respiratory diseases, with deep knowledge of Chinese and U.S. regulatory requirements and extensive experience in global drug registration processes.

Dr. Dow is a board-certified Medical Oncologist with over 30 years of experience in clinical research and medicine, including classic chemotherapy agents, and modern products like molecular-targeted, checkpoint inhibitors and vaccines. Skilled in solid tumor studies both from a safety and response assessment perspective, Dow has led many FIH and early phase study in a wide variety of relapsed/refractory solid tumors providing not only medical monitoring but a strategic medical disease-oriented approach.

Brian Weinhaus is the Director of Illicit Trade Prevention for the United States at Philip Morris International (PMI), where he leads strategic efforts to combat illegal trade and protect the integrity of the company’s supply chain. His work focuses on complex investigations, risk mitigation, and building strong cross‑sector partnerships with government and industry stakeholders.

With deep expertise in brand protection, intelligence, and stakeholder engagement, Brian collaborates closely with law enforcement and regulatory partners to address global challenges related to counterfeiting, smuggling, and organized illicit networks. Prior to joining PMI, Brian held senior leadership roles at Moderna and with Homeland Security Investigations, where he directed large‑scale international investigations and intelligence programs, bringing more than two decades of experience in federal law enforcement and corporate security to his current role.

Dr. Cheryl Olson is a behavioral scientist internationally recognized for her work on health risk behaviors and the influence of media on youth. She earned a doctorate in health and social behavior from the Harvard School of Public Health, and a master’s degree in community health education from the University of Minnesota. Cheryl spent 15 years on the psychiatry faculty at Massachusetts General Hospital/Harvard Medical School, where she co-directed the Center for Mental Health and Media.

Along with academic work, Cheryl has decades of experience making scientific content meaningful and engaging for a variety of target audiences. She has written/edited a half-dozen popular books on health, and several dozen scientific articles. Her work has appeared in the New York Times, Parents magazine, WNYC (NPR) and Tobacco Reporter. She has advised foundations, universities, politicians and companies on health communication and engagement strategies.

Cheryl’s work in tobacco/nicotine includes developing the influential QuitAssist smoking cessation program for Philip Morris USA, and a CME course on tobacco harm reduction for Physicians Research Institute. As a consultant with McKinney Regulatory Science Advisors, she designed and conducted perception/intention studies on various reduced-risk nicotine products; some involved vulnerable groups such as people in custody and older persons who smoke. Cheryl currently works as a regulatory scientist for Womble Bond Dickinson, based remotely in Richmond, Virginia.

Candy is a practical problem-solver and collaborative team-builder who has worked with the SQC team since 2005. He brings clarity to complex situations, getting teams and suppliers to perform, and drives delivery in uncertain or challenging conditions. Committed to achieving tangible results for customers, Candy has supported projects for organisations including the Prudential, M&G, Ageas, Deutsche Bank, HSBC, BT, Vodafone, and O2.

Dudley Tabakin is the Founder and Chief Executive Officer at VivoSense, where he leads overall company strategy, operations, and the advancement of wearable sensor solutions in clinical research. He works closely with cross-functional teams to guide the integration of digital measures into global clinical trials and to support pharmaceutical partners in leveraging sensor-based data to inform development decisions. In his role, Dudley is actively engaged with sponsors and industry stakeholders to shape how wearable technologies are operationalized within clinical development programs, helping bridge scientific innovation with real-world implementation.